Jonathan Kaufman, MD, Emory University School of Medicine, Atlanta, GA, briefly highlights preliminary findings from the Phase II randomized GRIFFIN trial (NCT02874742) in eligible newly diagnosed multiple myeloma patients. In this video, Dr Kaufman provides an update on the longer follow-up of the GRIFFIN study, where daratumumab is added to a lenalidomide, bortezomib and dexamethasone (RVd) backbone. Dr Kaufman draws focus on the ongoing improvements in deep responses, MRD negativity rate, and gives further input from a toxicity perspective. This interview took place at the 63rd ASH Annual Meeting and Exposition, Atlanta, 2021.